Single User License
INR 130920
Site License
INR 261840
Corporate User License
INR 392760

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Chronic Plaque Psoriasis-Pipeline Review, H2 2015

Chronic Plaque Psoriasis-Pipeline Review, H2 2015


  • Products Id :- GMDHC6862IDB
  • |
  • Pages: 125
  • |
  • July 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Chronic Plaque Psoriasis-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Chronic Plaque Psoriasis-Pipeline Review, H2 2015', provides an overview of the Chronic Plaque Psoriasis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Plaque Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Plaque Psoriasis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Chronic Plaque Psoriasis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Chronic Plaque Psoriasis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Chronic Plaque Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Chronic Plaque Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Chronic Plaque Psoriasis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Chronic Plaque Psoriasis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Chronic Plaque Psoriasis Overview 9

Therapeutics Development 10

Pipeline Products for Chronic Plaque Psoriasis-Overview 10

Pipeline Products for Chronic Plaque Psoriasis-Comparative Analysis 11

Chronic Plaque Psoriasis-Therapeutics under Development by Companies 12

Chronic Plaque Psoriasis-Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Chronic Plaque Psoriasis-Products under Development by Companies 17

Chronic Plaque Psoriasis-Companies Involved in Therapeutics Development 19

AbGenomics International, Inc. 19

Almirall, S.A. 20

Boehringer Ingelheim GmbH 21

Cellceutix Corporation 22

Coherus BioSciences, Inc. 23

Eli Lilly and Company 24

GlaxoSmithKline Plc 25

Johnson & Johnson 26

Mitsubishi Tanabe Pharma Corporation 27

Novartis AG 28

OPKO Health, Inc. 29

Pfizer Inc. 30

Sandoz International GmbH 31

Sun Pharma Advanced Research Company Ltd. 32

Takeda Pharmaceutical Company Limited 33

UCB S.A. 34

XenoPort, Inc. 35

Chronic Plaque Psoriasis-Therapeutics Assessment 36

Assessment by Monotherapy Products 36

Assessment by Target 37

Assessment by Mechanism of Action 39

Assessment by Route of Administration 41

Assessment by Molecule Type 43

Drug Profiles 45

AbGn-168H-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

adalimumab biosimilar-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

adalimumab biosimilar-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

baricitinib-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

BI-655066-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

C-82-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

certolizumab pegol-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

CJM-112-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

COVA-322-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

dimethyl fumarate-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

etanercept biosimilar-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

etanercept biosimilar-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

etanercept biosimilar-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

GSK-2831781-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

ixekizumab-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

KM-133-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

lunacalcipol-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

MT-1303-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

namilumab-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

orilotimod potassium-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

tildrakizumab-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

tofacitinib-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

XP-23829-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

Chronic Plaque Psoriasis-Recent Pipeline Updates 84

Chronic Plaque Psoriasis-Dormant Projects 111

Chronic Plaque Psoriasis-Discontinued Products 113

Chronic Plaque Psoriasis-Product Development Milestones 114

Featured News & Press Releases 114

Jun 08, 2015: Pfizer Announces 12 Presentations Including New Research Data on Tofacitinib for Chronic Plaque Psoriasis and Atopic Dermatitis at World Congress of Dermatology 114

Feb 04, 2015: Pfizer Announces FDA Acceptance For Review Of Supplemental New Drug Application For Oral XELJANZ (tofacitinib citrate) For Adult Patients With Moderate To Severe Chronic Plaque Psoriasis 116

Jul 16, 2014: Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 (Investigational Etanercept Biosimilar) In Chronic Plaque Psoriasis 116

May 23, 2014: Pfizer Announces Detailed Results For Phase 3 OPT Retreatment Study Of Tofacitinib In Adults With Moderate-To-Severe Chronic Plaque Psoriasis 117

Apr 22, 2014: Pfizer Announces Positive Top-Line Results from Two Phase 3 Trials of Tofacitinib in Adults with Moderate-to-Severe Chronic Plaque Psoriasis 119

Mar 22, 2014: Pfizer Announces Detailed Results of OPT Compare Phase 3 Study of Tofacitinib 5 mg and 10 mg Twice Daily Compared to High-Dose ENBREL in Adults with Moderate-to-Severe Chronic Plaque Psoriasis 120

Mar 28, 2012: Lilly's Ixekizumab Met Primary Endpoint In Phase II Study In Patients With Chronic Plaque Psoriasis 122

Appendix 124

Methodology 124

Coverage 124

Secondary Research 124

Primary Research 124

Expert Panel Validation 124

Contact Us 124

Disclaimer 125

List of Tables

Number of Products under Development for Chronic Plaque Psoriasis, H2 2015 10

Number of Products under Development for Chronic Plaque Psoriasis-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 13

Comparative Analysis by Late Stage Development, H2 2015 14

Comparative Analysis by Clinical Stage Development, H2 2015 15

Comparative Analysis by Early Stage Development, H2 2015 16

Products under Development by Companies, H2 2015 17

Products under Development by Companies, H2 2015 (Contd..1) 18

Chronic Plaque Psoriasis-Pipeline by AbGenomics International, Inc., H2 2015 19

Chronic Plaque Psoriasis-Pipeline by Almirall, S.A., H2 2015 20

Chronic Plaque Psoriasis-Pipeline by Boehringer Ingelheim GmbH, H2 2015 21

Chronic Plaque Psoriasis-Pipeline by Cellceutix Corporation, H2 2015 22

Chronic Plaque Psoriasis-Pipeline by Coherus BioSciences, Inc., H2 2015 23

Chronic Plaque Psoriasis-Pipeline by Eli Lilly and Company, H2 2015 24

Chronic Plaque Psoriasis-Pipeline by GlaxoSmithKline Plc, H2 2015 25

Chronic Plaque Psoriasis-Pipeline by Johnson & Johnson, H2 2015 26

Chronic Plaque Psoriasis-Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015 27

Chronic Plaque Psoriasis-Pipeline by Novartis AG, H2 2015 28

Chronic Plaque Psoriasis-Pipeline by OPKO Health, Inc., H2 2015 29

Chronic Plaque Psoriasis-Pipeline by Pfizer Inc., H2 2015 30

Chronic Plaque Psoriasis-Pipeline by Sandoz International GmbH, H2 2015 31

Chronic Plaque Psoriasis-Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015 32

Chronic Plaque Psoriasis-Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 33

Chronic Plaque Psoriasis-Pipeline by UCB S.A., H2 2015 34

Chronic Plaque Psoriasis-Pipeline by XenoPort, Inc., H2 2015 35

Assessment by Monotherapy Products, H2 2015 36

Number of Products by Stage and Target, H2 2015 38

Number of Products by Stage and Mechanism of Action, H2 2015 40

Number of Products by Stage and Route of Administration, H2 2015 42

Number of Products by Stage and Molecule Type, H2 2015 44

Chronic Plaque Psoriasis Therapeutics-Recent Pipeline Updates, H2 2015 84

Chronic Plaque Psoriasis-Dormant Projects, H2 2015 111

Chronic Plaque Psoriasis-Dormant Projects (Contd..1), H2 2015 112

Chronic Plaque Psoriasis-Discontinued Products, H2 2015 113

List of Figures

Number of Products under Development for Chronic Plaque Psoriasis, H2 2015 10

Number of Products under Development for Chronic Plaque Psoriasis-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 12

Comparative Analysis by Late Stage Development, H2 2015 14

Comparative Analysis by Clinical Stage Development, H2 2015 15

Assessment by Monotherapy Products, H2 2015 36

Number of Products by Top 10 Targets, H2 2015 37

Number of Products by Stage and Top 10 Targets, H2 2015 37

Number of Products by Top 10 Mechanism of Actions, H2 2015 39

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 39

Number of Products by Top 10 Routes of Administration, H2 2015 41

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 41

Number of Products by Top 10 Molecule Types, H2 2015 43

Number of Products by Stage and Top 10 Molecule Types, H2 2015 43

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbGenomics International, Inc.

Almirall, S.A.

Boehringer Ingelheim GmbH

Cellceutix Corporation

Coherus BioSciences, Inc.

Eli Lilly and Company

GlaxoSmithKline Plc

Johnson & Johnson

Mitsubishi Tanabe Pharma Corporation

Novartis AG

OPKO Health, Inc.

Pfizer Inc.

Sandoz International GmbH

Sun Pharma Advanced Research Company Ltd.

Takeda Pharmaceutical Company Limited

UCB S.A.

XenoPort, Inc.

Chronic Plaque Psoriasis Therapeutic Products under Development, Key Players in Chronic Plaque Psoriasis Therapeutics, Chronic Plaque Psoriasis Pipeline Overview, Chronic Plaque Psoriasis Pipeline, Chronic Plaque Psoriasis Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com